Global Artificial Heart Market Size By Type (Ventricular Assist Device (VAD), Total Artificial Heart), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

lobal Artificial Heart Market Report Description

The Global Artificial Heart Market was valued at USD 2.4 billion in 2023 and is projected to reach USD 6.9 billion by 2031, growing at a CAGR of 14.2% from 2023 to 2031. The rising prevalence of cardiovascular diseases, coupled with the increasing incidence of heart failure and organ donor shortages, is fueling the demand for artificial hearts. Continuous advancements in biomaterials, miniaturization technologies, and mechanical circulatory support systems are further accelerating market growth. The growing geriatric population and increased awareness of organ transplant alternatives are expected to support long-term expansion in this sector.

Drivers:

1. Rising Burden of Cardiovascular Diseases:

The increasing incidence of heart-related ailments such as cardiomyopathy, coronary artery disease, and heart failure is a primary factor driving the demand for artificial hearts as a life-sustaining option for patients awaiting heart transplants.

2. Organ Donor Shortage:

Globally, the gap between organ supply and demand is widening. Artificial hearts serve as critical bridge-to-transplant and destination therapy solutions, providing extended survival and improved quality of life for patients.

3. Technological Advancements in Heart Assist Devices:

Innovations in Total Artificial Heart (TAH) systems and Ventricular Assist Devices (VADs), including improved battery life, biocompatibility, and smart monitoring, are boosting adoption rates, especially in developed healthcare markets.

Restraints:

1. High Costs and Affordability Issues:

The cost of artificial heart devices and the accompanying surgical procedures remain significantly high, restricting access for patients in low- and middle-income countries.

2. Post-operative Complications and Risk Factors:

Despite advancements, patients remain vulnerable to complications such as bleeding, infection, thromboembolism, and mechanical failure, which can hinder market growth.

Opportunity:

1. Emerging Markets and Healthcare Investments:

Countries in Asia-Pacific, Latin America, and the Middle East are investing heavily in healthcare infrastructure. The growing penetration of advanced cardiac care in these regions presents lucrative growth opportunities.

2. Integration of AI and Remote Monitoring:

The application of artificial intelligence and smart sensor integration in heart support systems for real-time monitoring is paving the way for safer and more personalized treatment, offering a new dimension of opportunity.

Market by System Type Insights:

The Total Artificial Heart (TAH) segment held the largest market share in 2023 due to its ability to fully replace the heart's function in patients with end-stage biventricular heart failure. TAHs are especially vital when both left and right ventricles are compromised. The Left Ventricular Assist Devices (LVADs) segment, however, is expected to witness the highest growth rate due to increasing adoption as a bridge-to-transplant therapy and destination therapy in patients who are not eligible for heart transplantation.

Market by End-use Insights:

Hospitals and Cardiac Centers dominated the end-use segment in 2023, holding over 65% of the market share, owing to the availability of skilled professionals, advanced cardiac care infrastructure, and post-surgical recovery units. Ambulatory Surgical Centers (ASCs) are anticipated to grow significantly during the forecast period, driven by shorter recovery times, lower operational costs, and the increasing miniaturization of heart assist devices.

Market by Regional Insights:

North America led the global artificial heart market in 2023, supported by advanced healthcare infrastructure, strong presence of key market players, and favorable reimbursement policies. Europe followed closely, driven by government-funded healthcare systems and high awareness levels. The Asia-Pacific region is expected to be the fastest-growing market through 2031, driven by rapid urbanization, improving healthcare access, and increasing medical tourism.

Competitive Scenario:

Prominent companies in the global artificial heart market include SynCardia Systems LLC, Abbott Laboratories, Medtronic plc, Jarvik Heart, Inc., BiVACOR Inc., CARMAT, Evaheart, Inc., Abiomed Inc., and CH Biomedical (USA) Inc. These players are heavily investing in R&D, clinical trials, and regulatory approvals to expand their product portfolios. Noteworthy developments include:

In 2023, CARMAT received CE marking for its Aeson total artificial heart, enabling commercial use in European countries.

Abiomed Inc. launched a next-generation Impella device with enhanced durability and remote telemetry features.

SynCardia Systems LLC expanded its distribution network in Asia-Pacific in 2024 to increase market penetration.

Scope of Work – Global Artificial Heart Market

Report Metric Details

Market Size (2023) USD 2.4 billion

Projected Market Size (2031) USD 6.9 billion

CAGR (2023–2031) 14.2%

Key Segments By System Type (TAH, LVAD, RVAD), By End-use (Hospitals, ASCs)

Growth Drivers Rising cardiovascular disease prevalence, donor shortage, innovation in heart-assist tech

Opportunities Expansion in emerging markets, AI-enabled smart heart devices

Key Market Developments:

2023: BiVACOR Inc. announced successful preclinical trials for its biventricular artificial heart.

2024: Jarvik Heart, Inc. launched a pediatric version of its VAD for compassionate use in children under